Mike Rea

Mike Rea, a pharma consultant and head of Idea Pharma, shares insights from his personal journey through medical setbacks that reshaped his career. The conversation shifts to President Trump's proposed drug policies targeting China, stirring a debate on innovation versus protectionism. They also dive into the game-changing potential of the PD-1 VEGF inhibitor Ivanesimab, and discuss the leadership changes at Novo Nordisk, with implications for Alzheimer's research. Health challenges and the importance of patient advocacy in epilepsy treatment add a deeply personal touch.